Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_01903 |
| Species: | Homo sapiens |
| Position : | chr8:143015000-143025000 |
| Year: | 2025 |
| Title: | Nuclear PD-L1 drives IFN-?|??-promoted lung metastasis of triple-negative breast cancer via POLR2A-mediated transcriptional activation of LY6E |
| Genome Build: | hg38 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | lung adenocarcinoma |
| PMID: | 41388312 |
| MONDO: | MONDO:0005032 |
| Tissue: | Lung |
| Tissue Ontology ID: | UBERON:0002048 |
| Cell Source: | A549 cell line |
| CVCL ID: | CVCL_0023 |
| Cell Type: | lung adenocarcinoma cell |
| Cell Ontology ID: | CL:0001069 |
| Experiment Type: | Enhancer activity assay, TF binding assay |
| High Throughput Method: | ChIP-seq, RNA-seq |
| Low Throughput Method: | Luciferase Reporter Assay, ChIP-RT-qPCR, RT-RT-qPCR, Western blot |
| Target gene : | LY6E |
| TF name : |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|